HC Wainwright Brokers Boost Earnings Estimates for RCUS

Arcus Biosciences, Inc. (NYSE:RCUS) – HC Wainwright increased their Q1 2025 earnings estimates for shares of Arcus Biosciences in a report released on Wednesday, February 26th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($1.12) per share for the quarter, up from their previous estimate of ($1.30). HC Wainwright currently has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. HC Wainwright also issued estimates for Arcus Biosciences’ Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($0.96) EPS, FY2025 earnings at ($3.97) EPS, FY2026 earnings at ($4.50) EPS, FY2027 earnings at ($4.67) EPS, FY2028 earnings at ($2.89) EPS and FY2029 earnings at ($1.96) EPS.

Other analysts have also recently issued research reports about the stock. Bank of America dropped their price objective on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Wednesday, February 19th. Wedbush reiterated an “outperform” rating and issued a $36.00 price objective on shares of Arcus Biosciences in a research note on Thursday, November 7th. Finally, Morgan Stanley dropped their price objective on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $30.25.

Arcus Biosciences Price Performance

Shares of Arcus Biosciences stock opened at $10.89 on Friday. Arcus Biosciences has a twelve month low of $9.85 and a twelve month high of $20.00. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. The company has a 50-day simple moving average of $13.37 and a two-hundred day simple moving average of $15.40. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of -3.46 and a beta of 0.84.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.03) earnings per share for the quarter, topping the consensus estimate of ($1.17) by $0.14. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The business had revenue of $36.00 million during the quarter, compared to analysts’ expectations of $29.38 million.

Insider Activity

In related news, Director Yasunori Kaneko acquired 20,000 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was acquired at an average cost of $10.06 per share, for a total transaction of $201,200.00. Following the transaction, the director now directly owns 28,400 shares in the company, valued at $285,704. This trade represents a 238.10 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Robert C. Goeltz II sold 3,594 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total transaction of $53,910.00. Following the transaction, the chief financial officer now owns 60,138 shares of the company’s stock, valued at approximately $902,070. This represents a 5.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 12.30% of the company’s stock.

Hedge Funds Weigh In On Arcus Biosciences

A number of institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Arcus Biosciences by 2.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,007 shares of the company’s stock worth $506,000 after purchasing an additional 833 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Arcus Biosciences by 2.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,781 shares of the company’s stock worth $471,000 after purchasing an additional 843 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Arcus Biosciences by 2.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 43,685 shares of the company’s stock worth $668,000 after acquiring an additional 1,117 shares during the last quarter. R Squared Ltd bought a new stake in Arcus Biosciences during the 4th quarter worth approximately $26,000. Finally, Teacher Retirement System of Texas grew its holdings in Arcus Biosciences by 19.2% during the 4th quarter. Teacher Retirement System of Texas now owns 14,952 shares of the company’s stock worth $223,000 after acquiring an additional 2,410 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.